glp-1 and liver cirrhosis Your Liver: What to Monitor While on Semaglutide or Tirzepatide GLP-1s Gain Ground in Liver

In a head-to-head trial against semaglutide (the SURPASS-2 trial), tirzepatide produced significantly greater weight loss, with participants taking the highest dose of tirzepatide losing an average of 11.2 kg (24.7 lbs), compared to 5.7 kg (12.5 lbs) for those taking semaglutide 1 mg

While this is most common in people who use insulin, injection-technique guidance recommends rotating injection spots

Most studies demonstrated sustained weight loss and favorable glycemic control over treatment durations of 40-120 weeks

Timing: Some women choose to delay starting medications like tirzepatide until after theyre done breastfeeding

May Children Use Our Website